Search results
Percutaneous coronary intervention (PCI) using a metallic stent is the conventional treatment of coronary artery disease.
- Young Jin Youn, Sang Yong Yoo, Jun Won Lee, Sung Gyun Ahn, Seung Hwan Lee, Junghan Yoon, Jae Hyoung ...
- 10.4070/kcj.2019.0258
- 2020
- Korean Circ J. 2020 Apr; 50(4): 317-327.
Sep 12, 2022 · The aim of this clinical trial was to assess the efficacy and safety of three types (quarter‐, third‐, and half‐dose of the standard dose) of low‐dose triple combinations of amlodipine, telmisartan, and chlorthalidone after 8 weeks of administration in patients with essential hypertension. Go to: 2. METHODS.
- 10.1111/jch.14570
- 2022/10
Dec 23, 2019 · Correspondence to Junghan Yoon, MD, PhD. Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, 20, Ilsan-ro, Wonju 26426, Korea. Email: jyoon@yonsei.ac.kr
- Young Jin Youn, Sang Yong Yoo, Jun Won Lee, Sung Gyun Ahn, Seung Hwan Lee, Junghan Yoon, Jae Hyoung ...
- 2020
The primary endpoint was major adverse cardiac events (MACE), which was a composite of death, myocardial infarction (MI), and target lesion revascularization (TLR) at 5 years. We enrolled 38 patients in the Genoss DES group and 39 in the Promus Element group.
Seong Hwan AHN, Professor | Cited by 1,282 | of Chosun University, Gwangju | Read 101 publications | Contact Seong Hwan AHN.
May 5, 2021 · This study reported the 5-year clinical outcomes of the Genoss DES in the first-in-patient prospective, multicenter, randomized study. At 5 years, there were no significant differences in the rates of adverse clinical events among patients of the Genoss DES and Promus Element stent groups.
Seung Hwan HAN, Professor (Full) | Cited by 5,441 | | Read 222 publications | Contact Seung Hwan HAN
